Getting to the Heart of Prostate Cancer: Expanding Options to Improve Outcomes for Men of Color

This independent Medical Education Grant is being provided from Pfizer Inc. and Myovant Sciences Ltd.

Provided by Boston University School of Medicine and The University of Rhode Island College of Pharmacy

Release Date

May 31, 2022

Expiration Date

May 30, 2023

Program Description

Paradigms have shifted in prostate cancer care and the approach to metastatic prostate cancer has evolved immensely since 2014. Most of the treatment agents used in these settings are novel, hormonal-based agents that are given in combination with androgen deprivation therapy (ADT). As a backbone of therapy, ADT is given indefinitely in most men with metastatic disease. While ADT does not possess a similar side effect profile to that of traditional cytotoxic chemotherapy, it is not without risk- the long-term use of ADT has been associated with an increased risk of cardiovascular events. This risk may be compounded in black men, where the incidence of cardiovascular disease is higher.

This educational initiative will highlight the multidisciplinary approach to ensure appropriate care for patients and bring awareness to the risks of ADT. Furthermore, it will provide the resources for community practitioners, specialty providers, and patients to help identify and overcome disparities within the healthcare system.

Intended Audience

Urologists, Medical Oncologists, Nurse Practitioners, Physician Assistants, Pharmacists, Nurses, and other prostate cancer advanced practice providers.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

  1. Delineate clinical differences between GnRH agonists and antagonists used in different stages of prostate cancer
  2. Describe health disparities for Black men with prostate cancer and understand the prevalence of prostate cancer amongst Black men
  3. Assess the CV risk associated with ADT in patients with metastatic prostate cancer
  4. Integrate a multidisciplinary approach into treatment decisions for patients initiating ADT and novel antiandrogens for prostate cancer

Accreditor Disclosure of Conflicts of Interest Policy

Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Faculty Information

Mark Katz, MD
Program Course Director
Urology Specialist
Boston Medical Center
Assistant Professor of Urology, Boston University School of Medicine
Boston, Massachusetts

David Hughes, PharmD, BCOP
Clinical Pharmacy Manager – Specialty Programs/Oncology
PGY2 Oncology Residency Program Director
Boston Medical Center
Assistant Professor of Medicine, Boston University School of Medicine
Boston, Massachusetts

Alicia Morgans, MD
Genitourinary Medical Oncologist
Medical Director of Survivorship Program
Dana Farber Cancer Institute
Boston, Massachusetts

Faculty Disclosures

Dr. Mark Katz, CME Course Director, has no relevant financial relationships to disclose.

David Hughes, PharmD, discloses that he is a speaker for Abbvie and Amgen and receives grant support from Rigel Pharmaceuticals.

Dr. Alicia Morgans discloses that she is a consultant and speaker for Astellas, AstraZeneca, Bayer, Clovis, Dendreon, Myovant, Lantheus, Merck, Sanofi, Janssen, Novartis and Pfizer. She also receives grant and research support from Astellas, Bayer, Dendreon and Seattle Genetics.

Accreditor and Planning Committee Disclosures

Michael Burk, Senior Operations Manager, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Lynnette Henshaw, PharmD, a member of the planning committee, has no relevant financial relationships to disclose.

Mary-Jane Kanaczet, M. Ed., Director, Office of Continuing Professional Development, College of Pharmacy, University of Rhode Island, has no relevant financial relationships to disclose.

Jessica Martin, PhD, MWC, ELS, consultant medical editor, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Tashia Prince Lacombe, NP, Nurse Course Advisor, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Jasmine Patel, PharmD, a member of the planning committee, receives grant support from Pfizer and is on the advisory board for Myovant.

Carmela A. Townsend, DNP, MS/MBA, RN, Lead Nurse Planner, Boston University School of Medicine Office of Continuing Medical Education, has no relevant financial relationships to disclose.

Accreditation Statements

acpeThe University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This is an application-based educational activity. Pharmacists will receive 1.25 contact hours (0.125 CEUS) for the educational activity. No partial credit is available.
UNIVERSAL ACTIVITY NUMBERS (UAN): 0060-9999-22-048-H01-P
Estimated Time to Complete: 75 minutes

Disclosure of Unlabeled Use

Faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.

Disclaimer

THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

Instructions on How to Earn Credit

Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

For information about the accreditation of this program, please contact Boston University School of Medicine’s Continuing Medical Education Office at cme@bu.edu.

Privacy Policy

To view Boston University’s Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/

© Trustees of Boston University, 2022